Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Intangible Assets
Identifiable non-physical assets such as patents, trademarks, licenses, and customer relationships.
Alumis Inc. Common StockNASDAQ: ALMS
Intangible Assets · Q2 FY2026 · quarter ended Jun 2026
Intangible assets falls 82.1% from a year ago
Intangible assets stood at $9.14M at the end of Q2 FY2026, down 82.1% from a year earlier and down 82.1% from the prior quarter.
Context
- Intangible assets amounted to 1.6% of total assets at the end of Q2 FY2026, down 6.7 pp from a year earlier.
- Intangible assets increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether intangible assets keeps falling in the next quarterly balance sheet after a -82.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Intangible Assets history
USD · from the balance sheet
- Latest · FY2025
- 50.96M USD
- Year-over-year change
- —
| Period | Period end | Intangible Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 50.96M | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Intangible Assets vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so intangible assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -82.1% is the lowest of 3, against a peer median of -12.3%.
- Intangible assets amounts to 1.6% of total assets for ALMS, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $24.16M USD | -8.9% | +18.3% | 4.8% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €20.11M EUR | — | — | 12.1% |
ALMSAlumis Inc. Common Stock | Jun 2026 | $9.14M USD | -82.1% | — | 1.6% |
| Mar 2026 | €45.64K EUR | -15.7% | -32.8% | 0.1% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
| Dec 2025 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | -12.3% | -7.2% | 0.0% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.